Abstract
Recent studies from our laboratory have shown that intravenous administration of human umbilical cord blood (HUCB) mononuclear cells to mice improved blood glucose levels, atherosclerosis and prostate cancer. In this study, we examined the effect of HUCB cells on the production of IL-10 levels in IL-10 knockout mice. It has been proposed that administration of IL-10 may be beneficial in the treatment of inflammatory bowl disease. The results show that mice treated with HUCB cells (100x106) produce IL-10, as demonstrated by both qualitative and quantitative analyses, and that the levels of this cytokine persisted until the mice were sacrificed (5.5 months after administration). Immunohistochemical staining of the intestine using HuNu antibody cocktail demonstrated the presence of HUCB cells in the knockout mouse. Although the mice did not receive any immunosuppression, there was no evidence of graftversus- host disease. Our data suggest that HUCB cells are capable of producing IL-10, and the use of these cells or HUCB may be indicated in the treatment of certain human diseases.
Keywords: Human umbilical cord blood, plasma IL-10 levels, IL-10 knockout mice, stem cells
Current Stem Cell Research & Therapy
Title: Administration of Human Umbilical Cord Blood Cells Produces Interleukin-10 (IL-10) in IL-10 Deficient Mice Without Immunosuppression
Volume: 5 Issue: 1
Author(s): Brian A. McCarthy, Alluru S. Reddi, Kathleen M. Coakley, Steven M. Nguyen, Rasha R. Nayal, Mohammad Javdan, Santanu Paul and Norman Ende
Affiliation:
Keywords: Human umbilical cord blood, plasma IL-10 levels, IL-10 knockout mice, stem cells
Abstract: Recent studies from our laboratory have shown that intravenous administration of human umbilical cord blood (HUCB) mononuclear cells to mice improved blood glucose levels, atherosclerosis and prostate cancer. In this study, we examined the effect of HUCB cells on the production of IL-10 levels in IL-10 knockout mice. It has been proposed that administration of IL-10 may be beneficial in the treatment of inflammatory bowl disease. The results show that mice treated with HUCB cells (100x106) produce IL-10, as demonstrated by both qualitative and quantitative analyses, and that the levels of this cytokine persisted until the mice were sacrificed (5.5 months after administration). Immunohistochemical staining of the intestine using HuNu antibody cocktail demonstrated the presence of HUCB cells in the knockout mouse. Although the mice did not receive any immunosuppression, there was no evidence of graftversus- host disease. Our data suggest that HUCB cells are capable of producing IL-10, and the use of these cells or HUCB may be indicated in the treatment of certain human diseases.
Export Options
About this article
Cite this article as:
McCarthy A. Brian, Reddi S. Alluru, Coakley M. Kathleen, Nguyen M. Steven, Nayal R. Rasha, Javdan Mohammad, Paul Santanu and Ende Norman, Administration of Human Umbilical Cord Blood Cells Produces Interleukin-10 (IL-10) in IL-10 Deficient Mice Without Immunosuppression, Current Stem Cell Research & Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/157488810790442868
DOI https://dx.doi.org/10.2174/157488810790442868 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Ultrasound Contrast Imaging in Cancer –Technical Aspects and Prospects
Current Molecular Imaging (Discontinued) Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Viruses in Semen and Male Genital Tissues - Consequences for the Reproductive System and Therapeutic Perspectives
Current Pharmaceutical Design Pathogenic Mechanisms and Therapeutic Strategies in Spinobulbar Muscular Atrophy
CNS & Neurological Disorders - Drug Targets Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Cancer Stem Cells and Colorectal Cancer: An Overview
Current Topics in Medicinal Chemistry Structural Analysis for Colchicine Binding Site-Targeted ATCAA Derivatives as Melanoma Antagonists
Medicinal Chemistry Cancer Biology Aspects of Computational Methods & Applications in Drug Discovery
Current Pharmaceutical Design Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry Design, Synthesis and Antiproliferative Activity of 2-Acetamidothiazole-5- carboxamide Derivatives
Medicinal Chemistry